European Radiology, Год журнала: 2022, Номер 33(3), С. 2089 - 2095
Опубликована: Сен. 24, 2022
Язык: Английский
Viruses, Год журнала: 2023, Номер 15(1), С. 175 - 175
Опубликована: Янв. 7, 2023
The clinical course and outcome of COVID-19 are highly variable, ranging from asymptomatic infections to severe disease death. Understanding the risk factors is relevant both in setting at epidemiological level. Here, we provide an overview host, viral environmental that have been shown or (in some cases) hypothesized be associated with outcomes. considered detail include age frailty, genetic polymorphisms, biological sex (and pregnancy), co- superinfections, non-communicable comorbidities, immunological history, microbiota, lifestyle patient; variation infecting dose; socioeconomic factors; air pollution. For each category, compile (sometimes conflicting) evidence for association factor outcomes (including strength effect) outline possible action mechanisms. We also discuss complex interactions between various factors.
Язык: Английский
Процитировано
74
Transplantation, Год журнала: 2022, Номер 106(12), С. 2426 - 2434
Опубликована: Сен. 19, 2022
Background. Solid organ transplant recipients (SOTr) are at increased risk for severe disease from coronavirus 2019 (COVID-19) compared with non-SOTr. Methods. We performed a retrospective cohort study between March 1, 2020, and March, 30, 2021, in an integrated healthcare system 4.3 million members aged ≥18 y including 5126 SOTr. Comparisons COVID-19 mortality, hospitalization, incidence were made SOTr non-SOTr, different organs. Multivariate analysis was to identify factors mortality hospitalization. Results. There 600 (kidney, liver, heart, lung) COVID-19. Per person-year of among 10.0% versus 7.6% non-SOTr ( P < 0.0001). Compared uninfected SOTr, infected older (57.1 ± 14.0 45.7 17.9 y, 0.001), predominantly Hispanic/Latino (58.8% 38.6%, 0.0001), hypertensive (77.0% 23.8%; diabetic (49.6% 13.0%; = 0.0009). had higher hospitalization (39.5% 6.0%; intensive care unit admission (29.1% 15.5%; (14.7% 1.8%; 0.0001) Older age (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.05-1.10), male gender (HR, 1.79; CI, 1.11-2.86), body mass index 1.04; 1.00-1.09; 0.047) associated COVID-19, whereas race, diabetes, number/type immunosuppressive medications not. Among the lowest liver 0.34; 0.16-0.73) highest lung 1.74; 0.68-4.42). Conclusions. have rates general population. outcomes distinct transplantation types.
Язык: Английский
Процитировано
31
The Journal of Heart and Lung Transplantation, Год журнала: 2022, Номер 41(9), С. 1237 - 1247
Опубликована: Июнь 19, 2022
Язык: Английский
Процитировано
25
Infection, Год журнала: 2022, Номер 51(3), С. 749 - 757
Опубликована: Сен. 9, 2022
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is currently the major threat for immunocompromised individuals. The course of COVID-19 in lung transplant recipients Omicron era remains unknown. aim study was to assess outcome and associated factors a German-wide multicenter approach. All affected individuals from January 1st March 20th, 2022 8 German centers during wave were collected. Baseline characteristics antiviral measures with outcome. Of 218 patients PCR-proven SARS-CoV-2 infection 166 (76%) received any early (< 7 days) therapy median (interquartile range 1-4) days after symptom onset. Most sotrovimab (57%), followed remdesivir (21%) molnupiravir (21%). An combination applied 45 Thirty-four (16%) developed or critical severity according WHO scale. In total, 14 (6.4%) died subsequently COVID-19. Neither vaccination antibody status, nor treatments Only age glomerular filtration rate < 30 ml/min/1.73m2 independent risk due an important recipients. particular, elderly impaired kidney function are at worse Prophylaxis highly need further improvement.
Язык: Английский
Процитировано
22
Journal of Cystic Fibrosis, Год журнала: 2022, Номер 21(4), С. e221 - e231
Опубликована: Июнь 13, 2022
Язык: Английский
Процитировано
20
Infection, Год журнала: 2023, Номер 51(5), С. 1481 - 1489
Опубликована: Март 16, 2023
Lung transplant (LTx) recipients are at risk for poor outcomes from coronavirus disease 2019 (COVID-19). The aim of the study was to assess outcome patients receiving pre-exposure prophylaxis (PrEP) with tixagevimab and cilgavimab after LTx.All LTx outpatient visits February 28th October 31st, 2022 two German centers were included. Baseline characteristics recorded followed until November 30rd, 2022. Infections SARS-CoV-2, severity, COVID-19-associated death compared between without PrEP.In total, 1438 included in analysis, 419 (29%) received PrEP. Patients PrEP older earlier transplantation, had lower glomerular filtration rates, levels SARS-CoV-2-S antibodies. In 535 (37%) developed SARS-CoV-2 infection during a follow-up median 209 days. Fewer infections occurred period (31% vs. 40%, p = 0.004). Breakthrough 77 (19%). 37 (8%) severe or critical. No difference severity COVID-19 observed There 15 deaths (n 1 PrEP). Compared matched controls, there non-significant towards moderate critical (p 0.184).The number Despite being higher worse associated mortality similar
Язык: Английский
Процитировано
12
International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(3), С. 1583 - 1583
Опубликована: Янв. 29, 2022
(1) Background: In COVID-19 survivors there is an increased prevalence of pulmonary fibrosis which the underlying molecular mechanisms are poorly understood; (2) Methods: this multicentric study, n = 12 patients who succumbed to due progressive respiratory failure were assigned early and late group (death within ≤7 >7 days hospitalization, respectively) compared 11 healthy controls; mRNA protein expression as well biological pathway analysis performed gain insights into evolution fibrogenesis in COVID-19; (3) Results: Median duration hospitalization until death was 3 (IQR25-75, 3-3.75) 14 (12.5-14) group, respectively. Fifty-eight out 770 analyzed genes showed a significantly altered signature controls time-dependent manner. The entire study BST2 IL1R1, independent time. activity inflammation-related pathways, while fibrosis-related (particularly PDGFRB) pathways dominated group; (4) Conclusions: After first week shift from pro-inflammatory fibrogenic severe COVID-19. IL1R1 PDGFRB may serve potential therapeutic targets future studies.
Язык: Английский
Процитировано
19
Viruses, Год журнала: 2024, Номер 16(2), С. 271 - 271
Опубликована: Фев. 8, 2024
Increased COVID-19-related morbidity and mortality have been reported in solid organ transplant recipients (SOTRs). Most studies are underpowered for rigorous matching. We report infections, hospitalization, ICU care, from COVID-19, pertinent vaccination data Swedish SOTRs 2020–2021. conducted a nationwide cohort study, encompassing all residents. were identified with ICD-10 codes immunosuppressant prescriptions. Comparison cohorts weighted based on propensity score built potential confounders (age, sex, comorbidities, socioeconomic factors, geography), which achieved good balance between non-SOTR groups. included 10,372,033 individuals, including 9073 SOTRs. Of the SARS-CoV-2 infected, 47.3% of 19% comparator individuals hospitalized. care was given to 8% infected 2% comparators. The case fatality rate 7.7% SOTRs, 6.2% comparison cohort, 1.3% unweighted cohort. had an increased risk contracting COVID-19 (HR = 1.15 p < 0.001), being hospitalized 2.89 receiving 4.59 dying 1.42 0.001). much higher than general population during Also compared comparators, hospitalized, dying. In Sweden, vaccinated earlier Lung worst outcomes. Excess among concentrated second half 2021.
Язык: Английский
Процитировано
4
Current Opinion in Infectious Diseases, Год журнала: 2025, Номер unknown
Опубликована: Фев. 10, 2025
Morbidity and mortality rates after lung transplantation still remain higher than other forms of solid organ transplantation, primarily due to a risk infections the development chronic allograft dysfunction. Thus, tiered approach highlighting most significant respiratory pathogens including common opportunistic along with diagnostic, treatment prevention strategies, vaccination prophylaxis is needed. The need for intense immunosuppressive therapy prevent rejection, coupled transplanted lung's constant exposure environment impaired local defence mechanisms leads frequent infections. Viral bacterial are while fungal mainly involve tracheobronchial tract but may be fatal in case disseminated disease. Some infectious agents known trigger acute rejection or contribute Invasive testing form bronchoscopy bronchoalveolar lavage standard increasing experience point care gained allow early preemptive therapy. Timely diagnosis, treatment, ongoing monitoring essential, this can difficult wide variety potential pathogens.
Язык: Английский
Процитировано
0
Transplant Infectious Disease, Год журнала: 2023, Номер 25(1)
Опубликована: Янв. 5, 2023
Lung transplant recipients (LTRs) are at increased risk for coronavirus disease 2019 (COVID-19)-associated complications.We aimed to describe the outcomes of polymerase chain reaction-documented severe acute respiratory syndrome 2 (SARS-CoV-2) infection in LTRs followed our institution from March 2020 July 2022. The primary outcome investigated was hospitalization or death COVID-19-related symptoms within 28 days diagnosis.Overall, 60 cases were included, which 18 (30%) reached outcome. Only one patient (2%) died. Anti-spike monoclonal antibodies (mAbs) administered as early treatment 36 patients (casirivimab/imdevimab = 2, sotrovimab 31, and tixagevimab/cilgavimab 3). Multivariate analysis revealed that age >60 years (p .003; odds ratio [OR] 9.41; confidence interval [CI] 2.52-41.05) associated with a higher outcome, while administration mAbs .030; OR 0.23; CI 0.06-0.87) lower risk. No effect vaccination SARS-CoV-2 variant observed. Forced expiratory volume 1 s forced vital capacity values did not decrease among 37 who had spirometry performed month after COVID-19.We observed relatively low morbidity mortality COVID-19 LTR. mAb better
Язык: Английский
Процитировано
7